方龙飞律师在2022年加入高赢国际律师事务所，是科技业务部与生命科学业务部的律师。
方律师代表生物技术和制药公司处理并购、技术交易、许可和战略合作以及融资交易。
Experience
Longfei’s experience includes representing:
- Innovent in a strategic collaboration with Eli Lilly to develop and commercialize programs worldwide outside Greater China
- Kelun-Biotech in a strategic partnership with Crescent Biopharma to develop and commercialize SKB105 and CR-001
- Leads Biolabs in its exclusive license agreement with Dianthus Therapeutics for LBL-047
- TransThera in its royalty-bearing patent assignment and research collaboration agreement with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors
- Syneron in its strategic collaboration with AstraZeneca
- Vincentage in its license agreement with Corxel Pharmaceuticals for a small molecule glucagon-like peptide-1 receptor agonist
- Duality in its exclusive option agreement with GSK for an ADC asset
- VelaVigo in its exclusive option agreement with Avenzo for an Nectin4/TROP2 bispecific ADC
- Leads Biolabs in an exclusive option and license agreement with a Oblenio Bio, a NewCo formed by Aditum Bio for a CD19xBCMAxCD3 tri-specific T-cell engager antibody for autoimmune diseases
- Chengdu Baiyu in an exclusive license agreement with Novartis
- Argo biopharma in two exclusive license and collaboration agreements with Novartis for cardiovascular assets
- Seagen in an exclusive worldwide license agreement for an ADC asset with Nona Biosciences
- Wuxi Biologics in a research service agreement with BioNTech SE to discover two targets of preclinical investigational monoclonal antibodies
- Biotheus Inc. in a strategic research collaboration, option and worldwide license agreement with BioNTech SE
- C4 Therapeutics in its Licensing Agreement with Betta Pharmaceuticals
- Duality Biologics in exclusive license and collaboration agreements for two ADC assets with BioNTech for upfront totaling $170 million, and milestone payments potentially totaling over $1.5 billion
- DualityBio Biologics in its exclusive option, license and collaboration agreement with BeiGene
- Luye Pharma Group in its license agreement with BeiGene
- Kelun-Biotech in its license and collaboration agreement with Merck & Co, Inc.
- Arthrosi Therapeutics in its acquisition by Sobi for $950 million upfront and $550 million in milestones
- Curon in acquisition of CN201 by Merck for $700 million upfront plus up to $600 million milestones
- Proteologix in its acquisition by Johnson & Johnson for $850 million in cash and additional milestone payment
- SEED Therapeutics in its Series A-3 financing
- KBP Biosciences in its sale to Novo Nordisk of ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, for up to $1.3 billion
- LionRock Capital in its acquisition of Haglöfs AB from ASICS Corporation
专业活动
方律师是一名合格的中国专利代理人。 他还是一名认证信息隐私专家 (CIPP/E)。
专业经验
在加入高赢之前，方律师曾在另一家领先的国际律师事务所工作，专注于代表客户处理跨境专利诉讼和知识产权、并购和商业交易。
在法学院就读期间，方律师担任《哥伦比亚科学技术法律评论》的编辑。
资历
教育背景
法学硕士2022
美国哥伦比亚大学
法学硕士2019
中国人民大学
工学学士2016
东华大学
文学学士2016
东华大学
执业资格
司法区
- 纽约
Related Content
- Press ReleaseMarch 16, 2026
Goodwin Advised Templewater on the Acquisition of The Women’s Clinic Group
- Press ReleaseJanuary 27, 2026
Goodwin Advises Kelun-Biotech in Strategic Partnership with Crescent Biopharma to Develop and Commercialize Novel Oncology Therapeutics
- Press ReleaseDecember 15, 2025
Goodwin Advises Arthrosi Therapeutics in Agreement to be Acquired by Sobi for $950 Million Upfront and $550 Million in Milestones
- Press ReleaseNovember 3, 2025
Goodwin Represents FountainVest in its Investment in SML Group
- Press ReleaseOctober 30, 2025
Goodwin Represents Nanjing Leads Biolabs on Exclusive License Agreement with Dianthus Therapeutics for LBL-047 for Up to $1 Billion
- Press ReleaseApril 23, 2025
Goodwin Guides Syneron Bio on Strategic Collaboration with AstraZeneca for $75 Million and up to $3.4 Billion in Milestones
- Press ReleaseApril 23, 2025
Goodwin Represents VelaVigo on $440 Million Second Out-Licensing Deal of a First-in-Class Bi-specific Antibody
- Press ReleaseJanuary 13, 2025
Goodwin Advises Kelun Biotech and Harbour BioMed on License Agreement with Windward Bio for an Anti-TSLP Fully Human Antibody for Immunological Diseases for up to $970 Million Upfront and in Milestone Payments